KTC
MRTX

Kistler-Tiffany Companies’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Kistler-Tiffany Companies’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$6.87K Hold
190
– – ﹤0.01% 735
2023
Q1 		$7.07K Hold
190
– – ﹤0.01% 662
2022
Q4 		$8.61K Hold
190
– – ﹤0.01% 643
2022
Q3 		$13K Hold
190
– – ﹤0.01% 571
2022
Q2 		$13K Hold
190
– – ﹤0.01% 561
2022
Q1 		$16K Hold
190
– – ﹤0.01% 551
2021
Q4 		$28K Buy
+190
New +$29.5K 0.01% 451

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Kistler-Tiffany Companies's MRTX Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Mirati Therapeutics, Inc. Common Stock (MRTX) position steady in Q2 2023 at 190 shares worth $6.87K. The position accounts for ﹤0.01% of the portfolio, ranked #735.

Kistler-Tiffany Companies first reported a position in MRTX in Q4 2021 and has held it in 7 quarters since. The position peaked at $28K in Q4 2021. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Kistler-Tiffany Companies held 190 shares of Mirati Therapeutics, Inc. Common Stock worth $6.87K as of Q2 2023.
  • Kistler-Tiffany Companies left its Mirati Therapeutics, Inc. Common Stock share count unchanged in Q2 2023.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #735 holding.
  • Kistler-Tiffany Companies first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and has held it in 7 quarters since.
  • Kistler-Tiffany Companies's Mirati Therapeutics, Inc. Common Stock position peaked at $28K in Q4 2021.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.